UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 7, 2024



OPTINOSE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation or Organization)

001-38241 (Commission File No.)

42-1771610 (I.R.S. Employer Identification No.)

1020 Stony Hill Road, Suite 300 Yardley, Pennsylvania 19067

(Address of principal executive offices and zip code)

(267) 364-3500 (Registrant's telephone number, including area code) (Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

П Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)) П

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Common stock, par value \$0.001 per share Trading symbol(s) OPTN

Name of each exchange on which registered Nasdag Global Select Market

Item 2.02 Results of Operations and Financial Condition.

On March 7, 2024, OptiNose, Inc. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

The information included in Item 2.02 (including Exhibit 99.1) of this Form 8-K, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any Company filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On March 7, 2024, the Company will present an updated Corporate Presentation during its financial results and corporate updates call. A copy of the presentation is attached as Exhibit 99.2 to this report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release issued by OptiNose, Inc., dated March 7, 2024
99.2	OptiNose, Inc. Corporate Presentation, dated March 7, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

OptiNose, Inc. By: /s/ Anthony Krick Anthony Krick Chief Accounting Officer

Date: March 7, 2024



Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PDUFA target action date is March 16, 2024, for the Company's sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis

Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE's current nasal polyps indication and there is no FDA-approved medication for these patients

Company reports fourth quarter and full year 2023 XHANCE net revenue of \$19.9 million and \$71.0 million

Conference call and webcast to be held today at 8:00 a.m. Eastern Time

YARDLEY, Pa., March 7, 2024 Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.

"Our first strategic focus for 2023 was working to secure the first-ever approval of a medication for patients with chronic sinusitis," stated CEO Ramy Mahmoud, MD, MPH. "Our regulatory and clinical teams have been responsive and timely during FDA's review as the agency works towards a target action date of March 16. In addition, during 2023 we worked hard to prepare our organization to make the most of the new opportunity. We revised operations in a variety of ways to better support a 2024 launch while also successfully increasing the efficiency of our business, as evidenced by XHANCE net revenues and operating expenses that both beat our initial expectations for full year 2023. With the target FDA action date in a matter of days, I am confident that we are prepared, if approved, to rapidly make the product available to millions of patients in need, starting in our specialty physician audience."

Fourth Quarter 2023 and Recent Highlights

Chronic Sinusitis Supplemental New Drug Application (sNDA) In May 2023, the Company announced that the U.S. Food and Drug Administration (FDA) accepted its sNDA for XHANCE® (fluticasone propionate) in the Exhalation Delivery System™ seeking a new indication for treatment of adults with chronic rhinosinusitis (commonly referred to as, chronic sinusitis). The assigned Prescription Drug User Fee Act (PDUFA) goal date is March 16, 2024.

Publication of ReOpen Clinical Program Results

In January 2024, the Company announced the publication of peer-reviewed data from the landmark ReOpen program evaluating the efficacy and safety of XHANCE in adult patients with chronic sinusitis in the Journal of Allergy and Clinical Immunology: In Practice. As detailed in the publication, both trials showed statistically significant improvement in symptoms, in inflammation inside the sinuses, and in the number of acute disease exacerbations that occurred in patients treated with XHANCE compared to patients receiving a vehicle combined with the Exhalation Delivery System (EDS-placebo).

Fourth Quarter and Full Year 2023 Financial Results

The Company reported \$19.9 million in pet revenue from sales of XHANCE during the three-month period ended December 31, 2023, a decrease of 5% compared to \$20.9 million during the three-month period ended December 31, 2022. This decrease was primarily driven by a decrease in shipments. For the twelve-month period ended December 31, 2023, the Company reported \$71.0 million in net revenue from sales of XHANCE, a decrease of 7% compared to \$76.3 million during the twelve-month period ended December 31, 2022.

Costs and Expenses and net (loss) income For the three-month and twelve-month periods ended December 31, 2023, research and development expenses were \$1.3 million and \$5.3 million, respectively. Selling, general and administrative expenses were \$19.0 million and \$79.8 million during the three-month and twelve-month periods ended December 31, 2023, respectively. In total, SG&A plus R&D expenses decreased by \$37.8 million, or 31%, to \$85.1 million for the twelve-month period ended December 31, 2023 when compared to the twelve-month period ended December 31, 2022 total of \$122.9 million.

The net loss for the three-month period ended December 31, 2023 was \$10.0 million, or \$0.09 per share (basic and diluted). The net loss for the twelve-month period ended December 31, 2023 was \$35.5 million, or \$0.32 per share (basic and diluted).

Balance Sheet

The Company had cash and cash equivalents of \$73.7 million as of December 31, 2023.

Corporate Guidance

First Quarter 2024 XHANCE Net Revenue The Company expects XHANCE net revenues for the first quarter 2024 will be approximately \$13.0 million.

Full Year 2024 XHANCE Net Revenue Average Net Revenue per Prescription The Company expects XHANCE average net revenue per prescription will be approximately \$220 for full year 2024.

Company to Host Conference Call

Members of the Company's leadership team will host a conference call and presentation to discuss financial results and corporate updates beginning at 8:00 a.m. Eastern Time today.

Participants may access the conference call live via webcast by visiting the Investors section of Optinose's website at http://ir.optinose.com/presentations. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a personal PIN that can be used to access the call. In addition, a replay of the webcast will be available on the Company website for 60 days following the event.

OptiNose, Inc. Condensed Consolidated Statement of Operations (in thousands, except share and per share data) (Unaudited)

		Three Months Ended December 31,			Year Ended December 31,		
		2023	2022	2023	2022		
Revenues:							
Net product revenues	\$	19,865	\$ 20,856	\$ 70,987	\$ 76,276		
Total revenues		19,865	20,856	70,987	76,276		
Costs and expenses:							
Cost of product sales		2,131	2,981	8,633	9,263		
Research and development		1,286	2,921	5,303	15,260		
Selling, general and administrative		18,960	23,310	79,799	107,649		
Total costs and expenses		22,377	29,212	93,735	132,172		
Loss from operations		(2,512)	(8,356)	(22,748)	(55,896)		
Other expense		7,455	6,793	12,735	18,937		
Net loss	\$	(9,967)	\$ (15,149)	\$ (35,483)	\$ (74,833)		
Net loss per share of common stock, basic and diluted	\$	(0.09)	\$ (0.17)	\$ (0.32)	\$ (0.87)		
Weighted average common shares outstanding, basic and diluted		112,311,983	9,496,091	112,080,062	85,900,139		

OptiNose, Inc. Condensed Consolidated Balance Sheet Data (in thousands)

	December 31, 2023		December 31, 2022		
Cash and cash equivalents	\$	73,684	\$	94,244	
Other assets		34,045		49,978	
Total assets	\$	107,729	\$	144,222	
Total current liabilities (1)		176,524	\$	178,729	
Other liabilities		17,811		22,116	
Total stockholders' equity		(86,606)		(56,623)	
Total liabilities and stockholders' equity	\$	107,729	\$	144,222	

(1) – All outstanding principal and fees payable upon maturity have been classified as a current liability in accordance with Generally Accepted Accounting Principles ("GAAP") because, as of the date hereof, the Company believes that it is probable that it will not be able to maintain compliance with certain covenants contained in its Amended and Restated Note Purchase Agreement for at least the next 12-months. As a result, the Company salidied financial statements for the year ended December 31, 2023 (2023 Audide Financial Statements) which will be filed after the is substantial doubt about the Company's ability to continue as a going concern (i.e., a "going concern" paragraph). Please relets to the Company's availity to continue as a going concern" paragraph. Please relets to the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (including the 2023 Audide Financial Statements) which will be filed after the issuance of this press release for additional information.

About Optinose

Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on Twitter and LinkedIn

About XHANCE

XHANCE is a drug-device combination product that uses the Exhalation Delivery System (also referred to as the EDS) designed to deliver a topical anti-inflammatory to the high and deep regions of the sinonasal XHANCE is a drug-device combination product that uses the Exhalation Delivery System (also referred to as the EUS) designed to deliver a topical anti-inflammatory to the high and deep regions of the sinonasal cavity, including sinuses and sinus drainage tracts where sinuses ventilate and drain. XHANCE is approved by the U.S. Food and Drug Administration for the treatment of chronic rhinosinusitis with nasal polyps in patients 18 years of age or older and has been studied for treatment of chronic sinusitis (notably including patients without polyps in the nasal cavity) in two phase 3 trials, ReOpen1 and ReOpen2. Results from these trials are the first ever that we are aware of that show improvement in both symptoms and inflammation inside the sinuses, and reduction in acute exacerbations of disease, with a nasal therapy for chronic sinusitis patients, including patients with or without nasal polyps. If approved, XHANCE may be the first drug ever FDA-approved for treatment of chronic rhinosinusitis either with or without nasal polyps.

Important Safety Information

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

- Local Nasal Adverse Reactions: epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
- Close monitoring for glaucoma and cataracts is warranted.
- Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur
- . Immunosuppression and Risk of Infection: potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use
- with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients. Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly. Patients with major risk factors for decreased bone mineral content should be monitored and treated with established standards of care. .

ADVERSE REACTIONS: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see full Prescribing Information, including Instructions for Use

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forwardlooking statements for this purpose and include, among others, statements relating to the potential benefits of XHANCE for the treatment of chronic sinusitis (also referred to as "chronic minosinusitis" and "chronic rhinosinusitis without nasal polyps"); the potential for XHANCE to the first FDA-approved drug treatment for chronic sinusitis and the potential benefits thereof; objectives and preparations to launch XHANCE, if approved, for the treatment of chronic sinusitis; potential non-compliance with certain covenants under the Amended and Restated Pharmakon Note Purchase Agreement and the consequences thereof; and other statements regarding the Company's future operations, financial performance, financial position, prospects, objectives, strategies and other future events. Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forwardlooking statements including, among others: physician and patient acceptance of XHANCE for its current and any potential future indication; the Company's ability to maintain adequate third-party reimbursement for XHANCE prescriptions and net revenues; the Company's ability to achieve its financial guidance; potential for varying interpretation of the results from the ReOpen program; uncertainties related to the clinical development program and regulatory approval of XHANCE for the treatment of chronic sinusitis relating to norther as a going concern; risks and uncertainties relating to intellectual property; and ther risks, uncertainties and other factors discussed under the caption "litem 1A. Risk Factors" and elsewhere in the Company's most recent

Optinose Investor Contact

Jonathan Neely jonathan.neely@optinose.com 267.521.0531





Corporate Presentation March 7, 2024

Forward-Looking Statements

This presentation and our accompanying remarks contain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to: the generation of XHANCE prescriptions and net revenues; prescriptions ind net revenues and factors impacting the generation of future prescriptions and net revenues; prescription, prescriptions and net revenues; prescription, prescriptions and net revenues; prescriptions] statements relating to: the generation of XHANCE prescriptions and net revenues; prescriptions and net revenues; prescriptions] statements relating to: the generation of XHANCE prescriptions; potential early year effects on price and volume related to patient insurance; impact of payor utilization management criteria; commercial strategies; projected XHANCE net revenues for first quarter of 2024; projected XHANCE across assistance program; the potential benefits of XHANCE for the treatment of chronic sinusitis; the potential for an FDA action on the sNDA in March 2024; the potential for XHANCE to be the first FDA-approved drug treatment for chronic sinusitis and the potential benefits of, such potential partnership; potential non-compliance with certain covenants under the A&R Pharmakon Note Purchase Agreement and the potential consequences thereof; and other statements regarding to our future operations, financial performance, prospects, intentions, strategies, objectives and other future events.

Forward-looking statements are based upon management's current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: impact of, and the uncertainties caused by, physician and patient acceptance of XHANCE for its current and any potential future indication; our ability to maintain adequate third party reimbursement for XHANCE for its current and any potential future indication; our ability to maintain adequate third party reimbursement for XHANCE for its current and any potential future indication; our ability to maintain adequate third party reimbursement for XHANCE may be smaller than expected; unexpected costs and expenses; our ability to achieve our financial guidance; potential for varying interpretation of the results from the ReOpen Program; uncertainties related to the clinical development program and regulatory approval of XHANCE for the treatment of chronic sinusitis; our ability to comply with the covenants and other terms of the A&R Pharmakon Note Purchase Agreement; our ability to continue as a going concern; risks and uncertainties and other factors discussed in the "Risk Factors" section and elsewhere in our most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission (SEC) (including our Form 10-K to be filed with the SEC on March 7, 2024) – which are available at http://www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements made in this presentation, speak only as of the date of this presentation, whether as a result of new information, future developments or otherwise.

2

Key Takeaways

Successfully executed our 2023 strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS

Chronic sinusitis is a 10-fold market opportunity for XHANCE

sNDA target action date next week (March 16, 2024)

Return to strong growth in 2024, if sNDA approved



\$71M FY 2023 XHANCE

Net Revenues

FY 2023 XHANCE Net Revenue per Prescription 538M


FY 2023 Operating Expense Reduction \$74M Cash and

equivalents as of

Dec. 31, 2023

optinose

Successful Development of XHANCE as the <u>First</u> FDA-approved Drug Treatment for Chronic Sinusitis Creates Multiple <u>New</u> Opportunities for Growth







ReOpen Clinical Program – Anticipated Next Steps and Recent Highlights



- PDUFA target action date is March 16, 2024
- ReOpen Program results published January 18 in The Journal of Allergy and Clinical Immunology: In Practice
 - Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2)

optinose







2023 Company Strategy

- For 2023, we focused on increasing business efficiency, maintaining profitable prescription volume and revenue, while preserving resources and capabilities needed in 2024 to launch the new Chronic Sinusitis indication into our ENT/Allergy specialist audience:
 - Reduced both commercial and non-commercial operating expenses by a total of ~\$38M, or more than 30%, compared to FY 2022; of which \$28 million was SG&A
 - Completed analyses that enabled January 2024 optimization of sales force alignment and distribution strategy to support new opportunity
 - We made changes in the second half of 2023 to our co-pay assistance program intended to reduce the number and proportion of unprofitable prescriptions
 - Changes to copay programs had the intended effect of producing better than expected XHANCE net revenues in Q4 2023, including an increased average net revenue per prescription

8

XHANCE Prescriptions – Fourth Quarter 2023 Changes to co-pay assistance reduced the number of <u>unprofitable</u> new and total prescriptions






XHANCE Prescriptions – Full Year 2023






Financial Review – Fourth Quarter 2023 Changes to co-pay assistance drove an 11% increase in revenue per prescription



Financial Review – Full Year 2023



Execution of our 2023 strategy yielded a more efficient business that outperformed guidance





Q1 and Full Year 2024 Financial Guidance

XHANCE Net Revenue

- Q1 2024 expected to be approximately ~\$13 million
- XHANCE Average Net Revenue per Prescription
 - FY 2024 expected to be approximately \$220

15

optinose





Key Takeaways

Successfully executed our 2023 strategy to prioritize the potential launch of XHANCE as the first-ever FDA approved drug treatment for CS

Chronic sinusitis is a 10-fold market opportunity for XHANCE

sNDA target action date next week (March 16, 2024)

Return to strong growth in 2024, if sNDA approved



\$71M FY 2023 XHANCE

Net Revenues

17

FY 2023 XHANCE Net Revenue per Prescription 538M

FY 2023 Operating Expense Reduction \$74M Cash and

equivalents as of

Dec. 31, 2023

optinose

Investor Relations – NASDAQ: OPTN







Corporate Presentation March 7, 2024